Patents by Inventor Guillaume Cottarel

Guillaume Cottarel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170335351
    Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 23, 2017
    Applicant: INTREXON CORPORATION
    Inventors: William J. COLEMAN, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
  • Patent number: 9745603
    Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 29, 2017
    Assignee: Intrexon Corporation
    Inventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
  • Publication number: 20170152529
    Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 1, 2017
    Applicant: INTREXON CORPORATION
    Inventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
  • Patent number: 9399783
    Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: July 26, 2016
    Assignee: INTREXON CORPORATION
    Inventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
  • Publication number: 20160160243
    Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.
    Type: Application
    Filed: January 7, 2016
    Publication date: June 9, 2016
    Applicant: Intrexon Corporation
    Inventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
  • Patent number: 9267158
    Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: February 23, 2016
    Assignee: Intrexon Corporation
    Inventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
  • Patent number: 9155792
    Abstract: The present invention is directed to the use of RecA inhibitors as antibiotic agents, and provides RecA inhibitors useful in treating infections. Also provided are various compositions and methods associated with RecA inhibition.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: October 13, 2015
    Assignee: Trustees of Boston University
    Inventors: Guillaume Cottarel, Jamey Wierzbowski, Kollol Pal, Michael Kohanski, Daniel Dwyer, James Collins, Michael Almstetter, Michael Thormann, Andreas Treml
  • Publication number: 20140273128
    Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Intrexon Corporation
    Inventors: William J. COLEMAN, Genevieve M. VIDANES, Guillaume COTTAREL, Sheela MULEY, Roy KAMIMURA, Akbar F. JAVAN, Jianping SUN, Eli S. GROBAN
  • Publication number: 20120088271
    Abstract: Methods and compositions for making stable recombinant yeast 2 ?m plasmids are provided. Homologous recombination is performed to clone a nucleic acid of interest into the yeast 2 ?m plasmid. Heterologous nucleic acid subsequences are recombined between an FLP and a REP2 gene of the plasmid.
    Type: Application
    Filed: September 29, 2011
    Publication date: April 12, 2012
    Applicant: Codexis, Inc.
    Inventors: Farzad Haerizadeh, Fernando Valle, Guillaume Cottarel
  • Publication number: 20110065898
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Application
    Filed: November 25, 2009
    Publication date: March 17, 2011
    Applicant: ARIAD Gene Therapeutics, Inc.
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
  • Publication number: 20110015137
    Abstract: The present invention provides RecA inhibitors, compositions containing them, systems for identifying or characterizing them, and methods of using them.
    Type: Application
    Filed: July 7, 2008
    Publication date: January 20, 2011
    Applicant: Trustees of Boston University
    Inventor: Guillaume Cottarel
  • Publication number: 20100234348
    Abstract: The present invention provides compounds that potentiate the activity of antibiotic agents, particularly quinolones such as norflaxin. The invention further provides compositions, e.g., pharmaceutical compositions, comprising the inventive compounds. The invention also provides compositions comprising an antibiotic (e.g., a quinolone) and a compound that potentiates activity of the antibiotic. The invention further provides methods of treating a subject comprising administering any of the inventive compounds or compositions to the subject. The invention also provides screening methods to identify compounds that potentiate the activity of an antibiotic, e.g., a quinolone.
    Type: Application
    Filed: August 2, 2007
    Publication date: September 16, 2010
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Guillaume Cottarel, Timothy S. Gardner, Xiaoguang Lei, John Porco, Scott E. Schaus, Jamey Wierzbowski, Kollol Pal
  • Publication number: 20100029597
    Abstract: The present invention is directed to the use of RecA inhibitors as antibiotic agents, and provides RecA inhibitors useful in treating infections. Also provided are various compositions and methods associated with RecA inhibition.
    Type: Application
    Filed: February 13, 2007
    Publication date: February 4, 2010
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, PURETECH VENTURES
    Inventors: Guillaume Cottarel, Jamey Wierzbowski, Kollol Pal, Michael Kohanski, Daniel Dwyer, James Collins, Michael Almstetter, Michael Thormann, Andreas Treml
  • Publication number: 20100028334
    Abstract: A pharmaceutical composition comprising an antimicrobial agent and an enhancer of an antimicrobial agent, wherein the enhancer of an antimicrobial agent is an inhibitor of gene, that by inactivating the gene product potentiates the effectiveness of the antimicrobial agent. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the antimicrobial agent is an antimicrobial peptide such as a polymyxin, for example but not limited to colistin. In some embodiments of the present invention provides methods to treat and/or prevent infection of a subject with a microorganism by administering a pharmaceutical composition comprising an antimicrobial agent and an enhancer of an antimicrobial agent. In some embodiments, the present invention provides methods to inhibit growth of a microorganism by administering a pharmaceutical composition comprising an antimicrobial agent and an enhancer of an antimicrobial agent.
    Type: Application
    Filed: December 13, 2007
    Publication date: February 4, 2010
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Guillaume Cottarel, Jamey Wierzbowski
  • Publication number: 20090264342
    Abstract: The present invention provides methods for identifying target genes whose partial or complete functional inactivation potentiates the activity of an antibiotic agent, e.g., a quinolone antibiotic. The invention further provides methods for identifying agents that modulate expression of target genes or that modulate activity of expression products of target genes. Agents identified according to various methods of the invention potentiate the activity of antibiotics such as quinolones, aminoglycosides, peptide antibiotics and ?-lactams. Also provided are agents that suppress and/or retard resistance to antibiotics. The inventive methods provide potentiating agents and compositions comprising potentiating agents and antibiotics. Such agents and compositions can be used for inhibiting growth or survival of a microbial cell or of treating a subject suffering from or susceptible to a microbial infection.
    Type: Application
    Filed: February 13, 2007
    Publication date: October 22, 2009
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, PURETECH VENTURES
    Inventors: Guillaume Cottarel, Jamey Wierzbowski, Kollol Pal, Michael Kohanski, Daniel Dwyer, James Collins, Michael Almstetter, Michael Thormann, Andreas Treml
  • Patent number: 7241613
    Abstract: The invention provides for novel polypeptides of Candida species found on the cell wall of the Candida organism. The invention further provides for methods of using these polypeptides, the genes encoding the polypeptides and fragments thereof for preparing antibodies, vaccines, therapeutic and diagnostic compositions.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: July 10, 2007
    Assignee: Oscient Pharmaceuticals Corporation
    Inventors: Debra A. Willins, Arturo J. Morales, Guillaume Cottarel, Qiandong Zeng, Christina Alberti-Segui
  • Publication number: 20050059803
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Application
    Filed: June 24, 2004
    Publication date: March 17, 2005
    Applicant: ARIAD Gene Therapeutics, Inc.
    Inventors: Vivian Berlin, Maria Chiu, Guillaume Cottarel, Veronique Damagnez
  • Publication number: 20030104362
    Abstract: The present invention relates to the discovery of novel cell cycle regulatory proteins from the human pathogen Candida.
    Type: Application
    Filed: May 5, 1998
    Publication date: June 5, 2003
    Inventors: GUILLAUME COTTAREL, VERONIQUE DAMAGNEZ, GIULIO DRAETTA
  • Publication number: 20030054370
    Abstract: The present invention is directed to a systematic in silico method to identify new coding sequences, including homologs of coding sequences, in S. cerevisiae and other organisms. The present invention is also directed to novel ORFs and the proteins encoded thereby identified using the in silico methods.
    Type: Application
    Filed: February 27, 2002
    Publication date: March 20, 2003
    Inventors: Qiandong Zeng, Marco M. Kessler, Guillaume Cottarel
  • Patent number: 6509152
    Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: January 21, 2003
    Assignee: Ariad Gene Therapeutics, Inc.
    Inventors: Vivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez